Why KRYS rose 4% since Nov 16
Up 4% from Nov 16 to Nov 20 while the S&P 500 fell 7%.
- Krystal Biotech rose 4% from Nov 16 to Nov 20. It rose 6% on Nov 18 alone.
KRYS's Quality Score fell 2 points on Fri, Nov 20, to 7. Buying slipped from its highest in 20 days (2 chart checks stopped).
Follow KRYS's trial news. Pro members can get an alert when Krystal Biotech files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 4% from Nov 16 to Nov 20 while the S&P 500 fell 7%.
| The company | Sales up 26% on the year |
| Latest filing | 8-K, Nov 2 |
Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.
Expected to report Tue Feb 16, before the open
1 more date ahead: the conference, for Pro members.
No shelf registration or at-the-market program on file in the last three years.
President, R&D Suma Krishnan sold 25,000 shares on Sep 4, under a planned sale. 13 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means
KRYS is #42 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 42 |
Share count against a year before: KRYS +2.3%, TARS +9%, CRSP +6%, MRNA +2.8%.
Expected to report Tue Feb 16, before the open (in 87 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $2.05 a share, from $2.66.
KRYS's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Its share count grew 5.5% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | -5.4% | -10.9% | -9.4% |
| Aug 3, 2026 | -6.0% | -8.4% | -4.3% |
| May 4, 2026 | -0.2% | +7.9% | +14.9% |
Sales grew in three of the last four years, to $389M in 2025. It made a profit in three of the five years.
RSI 47.3, MACD above signal, below both averages. Not scored.
One insider sold $8.2M across 8 filings in the last 6 months. No open-market buys on record. The newest:
4 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: KRYS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
“The biotechnology and pharmaceutical industries are highly competitive.”
KRYS scores 7 today, which Breakaway calls Average. It is #42 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Up 4% from Nov 16 to Nov 20 while the S&P 500 fell 7%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
KRYS scores 7 today, which Breakaway calls Average (6 to 10). That is #42 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KRYS's 7.
One insider sold $8.2M across 8 filings in the last 6 months. No open-market buys on record. The newest is Dino A. Rossi, Director, who sold $2.4M on Aug 14. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.